PDE11A Gene Polymorphism in Testicular Cancer: Sperm Parameters and Hormonal Profile

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2021 Mar 4

PMID 33661511

Citations 4

Authors

F Faja

F Finocchi

T Carlini

F Rizzo

F Pallotti

M Spaziani

G Balercia

A Lenzi

D Paoli

F Lombardo

Affiliations

Soon will be listed here.

Abstract

Purpose: Testicular germ cell tumours (TGCTs) is the most common malignancy among young adult males. The etiology is multifactorial and both environmental and genetic factors play an important role in the origin and development of TGCT. Genetic susceptibility may result from the interaction of multiple common and low-penetrance genetic variants and one of the main candidate genes is PDE11A. Many PDE11A polymorphisms were found responsible for a reduced PDE activity in TGCT patients, who often also display impaired hormone and sperm profile. The aim of this study was to investigate testicular function and PDE11A sequence in testicular cancer cases.

Methods: Semen analysis was performed in 116 patients with unilateral and bilateral sporadic TGCTs and in 120 cancer-free controls. We also investigated hormone profile and PDE11A polymorphisms using peripheral blood samples.

Results: Our data revealed that TGCT patients showed lower testosterone levels, higher gonadotropins levels and worse semen quality than controls, although the mean and the medians of sperm parameters are within the reference limits. PDE11A sequencing detected ten polymorphisms not yet associated with TGCTs before. Among these, G223A in homozygosity and A288G in heterozygosity were significantly associated with a lower risk of testicular tumour and they displayed a positive correlation with total sperm number.

Conclusions: Our findings highlight the key role of PDE11A in testis and suggest the presence of an underlying complex and fine molecular mechanism which controls testis-specific gene expression and susceptibility to testicular cancer.

Citing Articles

Phosphodiesterase Type 5 Inhibitors in Male Reproduction: Molecular Mechanisms and Clinical Implications for Fertility Management.

Kaltsas A, Dimitriadis F, Zachariou A, Sofikitis N, Chrisofos M Cells. 2025; 14(2).

PMID: 39851548 PMC: 11763789. DOI: 10.3390/cells14020120.

Genome-Wide DNA Methylation Analysis and Functional Validation of Litter Size Traits in Jining Grey Goats.

Yang C, He J, Mao J, Ren Y, Liu G, Wei C Genes (Basel). 2024; 15(3).

PMID: 38540412 PMC: 10970512. DOI: 10.3390/genes15030353.

Once upon a Testis: The Tale of Cyclic Nucleotide Phosphodiesterase in Testicular Cancers.

Campolo F, Assenza M, Venneri M, Barbagallo F Int J Mol Sci. 2023; 24(8).

PMID: 37108780 PMC: 10146088. DOI: 10.3390/ijms24087617.

The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.

Bolger G Front Endocrinol (Lausanne). 2022; 13:1024423.

PMID: 36313756 PMC: 9612118. DOI: 10.3389/fendo.2022.1024423.

Environmental disruptors and testicular cancer.

Faja F, Esteves S, Pallotti F, Cicolani G, Di Chiano S, Delli Paoli E Endocrine. 2022; 78(3):429-435.

PMID: 36036879 PMC: 9637059. DOI: 10.1007/s12020-022-03171-z.

References

Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin K . A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet. 2006; 38(7):794-800. DOI: 10.1038/ng1809. View

Fritz K, Weissbach L . Sperm parameters and ejaculation before and after operative treatment of patients with germ-cell testicular cancer. Fertil Steril. 1985; 43(3):451-4. DOI: 10.1016/s0015-0282(16)48448-7. View

Dieckmann K, Pichlmeier U . The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997; 80(10):1954-60. View

Medhamurthy R, Aravindan G, Moudgal N . Hemiorchidectomy leads to dramatic and immediate alterations in pituitary follicle-stimulating hormone secretion and the functional activity of the remaining testis in the adult male bonnet monkey (Macaca radiata). Biol Reprod. 1993; 49(4):743-9. DOI: 10.1095/biolreprod49.4.743. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Markey C, Rubin B, Soto A, Sonnenschein C . Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol. 2003; 83(1-5):235-44. DOI: 10.1016/s0960-0760(02)00272-8. View

de Bruin D, de Jong I, Arts E, Nuver J, Dullaart R, Sluiter W . Semen quality in men with disseminated testicular cancer: relation with human chorionic gonadotropin beta-subunit and pituitary gonadal hormones. Fertil Steril. 2008; 91(6):2481-6. DOI: 10.1016/j.fertnstert.2008.03.016. View

Pelloni M, Coltrinari G, Paoli D, Pallotti F, Lombardo F, Lenzi A . Differential expression of miRNAs in the seminal plasma and serum of testicular cancer patients. Endocrine. 2016; 57(3):518-527. DOI: 10.1007/s12020-016-1150-z. View

Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R . Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res. 2005; 17(3):216-23. DOI: 10.1038/sj.ijir.3901307. View

10.

Meirow D, Schenker J . Cancer and male infertility. Hum Reprod. 1995; 10(8):2017-22. DOI: 10.1093/oxfordjournals.humrep.a136228. View

11.

Botchan A, Hauser R, Yogev L, Gamzu R, Paz G, Lessing J . Testicular cancer and spermatogenesis. Hum Reprod. 1997; 12(4):755-8. DOI: 10.1093/humrep/12.4.755. View

12.

Bujan L, Walschaerts M, Moinard N, Hennebicq S, Saias J, Brugnon F . Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertil Steril. 2013; 100(3):673-80. DOI: 10.1016/j.fertnstert.2013.05.018. View

13.

Paoli D, Gilio B, Piroli E, Gallo M, Lombardo F, Dondero F . Testicular tumors as a possible cause of antisperm autoimmune response. Fertil Steril. 2008; 91(2):414-9. DOI: 10.1016/j.fertnstert.2007.11.084. View

14.

Kelly M . Does phosphodiesterase 11A (PDE11A) hold promise as a future therapeutic target?. Curr Pharm Des. 2014; 21(3):389-416. DOI: 10.2174/1381612820666140826114941. View

15.

Jacobsen R, Bostofte E, Engholm G, Hansen J, Olsen J, Skakkebaek N . Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ. 2000; 321(7264):789-92. PMC: 27489. DOI: 10.1136/bmj.321.7264.789. View

16.

Bizet P, Saias-Magnan J, Jouve E, Grillo J, Karsenty G, Metzler-Guillemain C . Sperm cryopreservation before cancer treatment: a 15-year monocentric experience. Reprod Biomed Online. 2012; 24(3):321-30. DOI: 10.1016/j.rbmo.2011.11.015. View

17.

Fukawa T, Kanayama H . Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018; 25(4):337-344. DOI: 10.1111/iju.13519. View

18.

Pallotti F, Pelloni M, Gianfrilli D, Lenzi A, Lombardo F, Paoli D . Mechanisms of Testicular Disruption from Exposure to Bisphenol A and Phtalates. J Clin Med. 2020; 9(2). PMC: 7074154. DOI: 10.3390/jcm9020471. View

19.

Kratz C, Mai P, Greene M . Familial testicular germ cell tumours. Best Pract Res Clin Endocrinol Metab. 2010; 24(3):503-13. PMC: 2939736. DOI: 10.1016/j.beem.2010.01.005. View

20.

Cabanero M, Laje G, Detera-Wadleigh S, McMahon F . Association study of phosphodiesterase genes in the Sequenced Treatment Alternatives to Relieve Depression sample. Pharmacogenet Genomics. 2009; 19(3):235-8. PMC: 2819180. DOI: 10.1097/FPC.0b013e328320a3e2. View